YU295A - PROCEDURES FOR PREVENTING PROTEIN DEGRADATION C - Google Patents

PROCEDURES FOR PREVENTING PROTEIN DEGRADATION C

Info

Publication number
YU295A
YU295A YU295A YU295A YU295A YU 295 A YU295 A YU 295A YU 295 A YU295 A YU 295A YU 295 A YU295 A YU 295A YU 295 A YU295 A YU 295A
Authority
YU
Yugoslavia
Prior art keywords
apc
present
procedures
preventing
protein degradation
Prior art date
Application number
YU295A
Other languages
Serbo-Croatian (sh)
Inventor
F.W. Prouty
J. Secnik
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22650141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU295(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of YU295A publication Critical patent/YU295A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4866Protein C (3.4.21.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6464Protein C (3.4.21.69)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

POSTUPCI ZA SPREČAVANJE DEGRADACIJE PROTEINA C - Ovaj pronalazak se odnosi na postupke za sprecavanje ili smanjivanje autodegradacije aktiviranog proteina C. Ovaj pronalazak je najbolje prikazan primerima vrSenjem prerade, prečiSćavanja i/ili skladiStenja aktiviranog proteina C na niskom pH, na primer na oko pH 6.3 do oko pH 6.5. Autodegradacija aPC može takodje biti smahjeha in-kubiranjem aPC u 3 M karbamidu (potpuna regeneracija aPC aktivnosti se pbstiže posle uklanjanja reagensa za denaturizaciju) ili inkubiranjem aPC u prisustvu ekstiemnih koncentracija soli. Ovaj pronalazak takodje obuhvata aPC formulacije koje održavaju aPC na niskom pH, u reagensu za denaturizaciju, ili na ekstremnim koncentracijama soli.METHODS FOR PREVENTING DEGRADATION OF PROTEIN C - The present invention relates to methods for preventing or reducing autodegradation of activated protein C. The present invention is best illustrated by examples of processing, purifying and / or storing activated protein C at low pH, for example at about pH 6.3 to about pH 6.5. Self-degradation of aPC can also be accomplished by incubating aPC in 3 M urea (complete regeneration of aPC activity is achieved after removal of the denaturing reagent) or by incubating aPC in the presence of extremal salt concentrations. The present invention also encompasses aPC formulations that maintain aPC at low pH, in denaturing reagent, or at extreme salt concentrations.

YU295A 1994-01-05 1995-01-04 PROCEDURES FOR PREVENTING PROTEIN DEGRADATION C YU295A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17783294A 1994-01-05 1994-01-05

Publications (1)

Publication Number Publication Date
YU295A true YU295A (en) 1997-09-30

Family

ID=22650141

Family Applications (1)

Application Number Title Priority Date Filing Date
YU295A YU295A (en) 1994-01-05 1995-01-04 PROCEDURES FOR PREVENTING PROTEIN DEGRADATION C

Country Status (29)

Country Link
EP (2) EP0662513B1 (en)
JP (1) JP3778588B2 (en)
KR (1) KR950032287A (en)
CN (1) CN1109891A (en)
AT (1) ATE201045T1 (en)
AU (1) AU1003195A (en)
BR (1) BR9500017A (en)
CA (1) CA2139468C (en)
CO (1) CO4600680A1 (en)
CZ (1) CZ1395A3 (en)
DE (2) DE69520844T2 (en)
DK (1) DK0662513T3 (en)
ES (1) ES2156190T3 (en)
FI (1) FI115635B (en)
GR (1) GR3036277T3 (en)
HU (1) HUT70465A (en)
IL (1) IL112236A (en)
LU (2) LU90992I2 (en)
NL (1) NL300108I2 (en)
NO (2) NO320157B1 (en)
NZ (1) NZ270271A (en)
PE (1) PE43995A1 (en)
PL (1) PL180703B1 (en)
PT (1) PT662513E (en)
RU (1) RU2167936C2 (en)
SI (1) SI0662513T1 (en)
UA (1) UA39178C2 (en)
YU (1) YU295A (en)
ZA (1) ZA9514B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA55448C2 (en) 1997-04-28 2003-04-15 Елі Ліллі Енд Компані Pharmaceutical formulations of activated protein с
EP1557463A1 (en) * 1997-04-28 2005-07-27 Eli Lilly & Company Improved methods for processing activated protein C
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
CA2410567A1 (en) 2000-05-24 2001-11-29 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
US20080125580A1 (en) * 2006-07-14 2008-05-29 Genentech, Inc. Refolding of Recombinant Proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950513A (en) * 1965-12-03 1976-04-13 Novo Terapeutisk Laboratorium A/S Process of stabilizing therapeutically useful plasmin solutions
US3557002A (en) * 1967-11-15 1971-01-19 Procter & Gamble Stabilized aqueous enzyme preparation
GB2105521A (en) * 1981-08-12 1983-03-23 Univ Surrey Antenna
AT402262B (en) * 1991-06-20 1997-03-25 Immuno Ag MEDICINAL ACTIVATED PROTEIN C

Also Published As

Publication number Publication date
NO950018L (en) 1995-07-06
SI0662513T1 (en) 2001-10-31
NL300108I2 (en) 2003-06-02
HU9500021D0 (en) 1995-03-28
FI115635B (en) 2005-06-15
PT662513E (en) 2001-08-30
CN1109891A (en) 1995-10-11
EP0662513A1 (en) 1995-07-12
PL306671A1 (en) 1995-07-10
NO2006006I1 (en) 2006-05-15
CZ1395A3 (en) 1995-07-12
HUT70465A (en) 1995-10-30
FI950044A0 (en) 1995-01-04
CA2139468A1 (en) 1995-07-06
PE43995A1 (en) 1995-12-15
DE10299053I1 (en) 2003-05-22
DK0662513T3 (en) 2001-05-28
BR9500017A (en) 1995-10-03
DE69520844D1 (en) 2001-06-13
KR950032287A (en) 1995-12-20
ES2156190T3 (en) 2001-06-16
CO4600680A1 (en) 1998-05-08
UA39178C2 (en) 2001-06-15
LU90993I2 (en) 2003-02-18
FI950044L (en) 1995-07-06
GR3036277T3 (en) 2001-10-31
NO320157B1 (en) 2005-11-07
LU90992I2 (en) 2003-02-18
AU1003195A (en) 1995-07-13
IL112236A (en) 1999-12-31
ZA9514B (en) 1996-07-03
IL112236A0 (en) 1995-03-30
JPH07206704A (en) 1995-08-08
EP1087011A2 (en) 2001-03-28
NL300108I1 (en) 2003-02-03
DE10299053I2 (en) 2004-04-01
PL180703B1 (en) 2001-03-30
CA2139468C (en) 2007-08-21
JP3778588B2 (en) 2006-05-24
RU95100178A (en) 1997-03-27
ATE201045T1 (en) 2001-05-15
RU2167936C2 (en) 2001-05-27
EP1087011A3 (en) 2002-02-06
DE69520844T2 (en) 2001-11-08
NO950018D0 (en) 1995-01-03
EP0662513B1 (en) 2001-05-09
NZ270271A (en) 1996-07-26

Similar Documents

Publication Publication Date Title
DE69907439D1 (en) Purification of proteins by ion exchange chromatography
DE69030449D1 (en) METHOD AND KIT FOR PURIFYING NUCLEIC ACID
EA199900980A1 (en) IMPROVED WAYS TO PREPARE ACTIVATED PROTEIN C
DE69316501D1 (en) Proteases for inhibiting and eliminating biofilm
DK0828753T3 (en) A1 / Fe treatment of a protein solution followed by membrane concentration
YU295A (en) PROCEDURES FOR PREVENTING PROTEIN DEGRADATION C
ES2152935T3 (en) METHOD TO DELETE THE COLORATION OF THE HUMAN SERICA ALBUMINE.
ATE86669T1 (en) COMPOSITION AND METHOD OF STABILIZING DINUCLEOTIDES.
ES2174481T3 (en) EMPLOYMENT OF SOLUTIONS CONTAINING ENZYMES FOR THE CLEANING OF FERMENTATION OR STORAGE TANKS.
DK0651791T3 (en) Process for purifying aqueous enzyme solution
ATE22651T1 (en) METHOD FOR CLEANING OR. ENRICHMENT OF BIOLOGICALLY ACTIVE PROTEINS AND MEANS SUITABLE FOR THIS.
TH19245A (en) How to prevent the breakdown of protein C
ATE100350T1 (en) PROCESS FOR PURIFICATION OF AQUEOUS BUFFER SOLUTIONS.